The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ROS1 rearrangement in non-small cell lung cancer (NSCLC): Prognostic and predicitve impact and genetic variability.
 
Matthias Scheffler
Honoraria - AstraZeneca; Boehringer Ingelheim
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Novartis
 
Anne Maria Schultheis
No Relationships to Disclose
 
Cristina Teixido
No Relationships to Disclose
 
Sebastian Yves Friedrich Michels
No Relationships to Disclose
 
Daniela Morales-Espinosa
No Relationships to Disclose
 
Santiago Viteri
No Relationships to Disclose
 
Sabine Merkelbach-Bruse
No Relationships to Disclose
 
Rieke Fischer
No Relationships to Disclose
 
Jana Fassunke
No Relationships to Disclose
 
Martin Sebastian
No Relationships to Disclose
 
Monika Heidi Serke
No Relationships to Disclose
 
Winfried Randerath
No Relationships to Disclose
 
Ulrich Gerigk
No Relationships to Disclose
 
Yon-Dschun Ko
No Relationships to Disclose
 
Stefan Krüger
No Relationships to Disclose
 
Roland Schnell
No Relationships to Disclose
 
Achim Rothe
No Relationships to Disclose
 
Rafael Rosell
No Relationships to Disclose
 
Reinhard Büttner
No Relationships to Disclose
 
Juergen Wolf
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; MSD Oncology; Novartis; Pfizer; Roche Pharma AG
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; MSD Oncology; Novartis; Pfizer; Roche Pharma AG
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Novartis (Inst); Pfizer (Inst); Roche Pharma AG (Inst)